(CercleFinance.com) – In a note on European biotechnology stocks, Oddo BHF indicates that it favors Valneva, as well as Abivax and Genfit, with ‘outperformance’ opinions and price targets raised to 12, 30 and 8.8 respectively euros.
“These three titles benefit from solid shareholders accompanied by a clinical and regulatory newsflow whose risk/reward seems attractive to us over the next 18 months,” explains the analyst in charge of the file.
Oddo BHF points out that the stock market performance of the sector at the start of 2023 was once again extremely heterogeneous. “A rebound in M&A operations is finally materializing, which should reinvigorate an apathetic sector,” he points out, however.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
